MedTrace Logo

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

NCT05332353 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-04-18

No results posted yet for this study

Summary

This prospective study aims at using Artificial intelligence to create a helpful unbiased machine learning-based model that predicts BCG unresponsiveness in high risk BCG-naïve NMIBC patients incorporating all potential clinico-pathological, radiological and/or molecular prognostic factors.

Conditions

Interventions

DRUG

Bacillus Calmette-Guerin

Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Osama Ezzat, Ass. lect. · Urology and Nephrology Center , Mansoura university

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-12-01
Completion
2023-12-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332353 on ClinicalTrials.gov